Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2014
Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responsesNicholas M Provine, Rafael A Larocca, Pablo Penaloza-MacMaster, et al.
The Journal of Clinical Investigation|October 8, 2021
Cross-protective immunity following coronavirus vaccination and coronavirus infectionTanushree Dangi, Nicole Palacio, Sarah Sanchez, et al.
Scientific Reports|January 11, 2018
Modeling tumor immunity of mouse glioblastoma by exhausted CD8<sup>+</sup> T cellsHiroshi Nakashima, Quazim A Alayo, Pablo Penaloza-MacMaster, et al.
Journal of Virology|February 12, 2016
Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody ResponsesNicholas M Provine, Alexander Badamchi-Zadeh, Christine A Bricault, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2020
A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2Xiaolei Cai, Aleksander Prominski, Yiliang Lin, et al.
Journal of Virology|March 9, 2018
Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus InfectionEryn Blass, Malika Aid, Amanda J Martinot, et al.
Journal of Virology|November 24, 2012
Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectorsWendy G Tan, Hyun-Tak Jin, Erin E West, et al.
Journal of Neuroinflammation|May 31, 2024
Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b<sup>+</sup> myeloid cellsGabriel Arellano, Eric Acuña, Eileah Loda, et al.
The Journal of Clinical Investigation|October 11, 2022
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibodyTanushree Dangi, Sarah Sanchez, Jacob Class, et al.
Journal of Virology|March 21, 2014
Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimensPablo Penaloza-MacMaster, Jeffrey E Teigler, Rebecca C Obeng, et al.
Pageof 7